| |
|
|
| Address |
480-2,JANGRIM 2-DONG, SAHA-GU, BUSAN |
| Home Page |
www.bi-nex.com
|
| Established |
1985. 3.21 |
Tel |
051-261-6611-4 |
| Listed |
2001. 8. 7 |
IR |
|
| Common shares O/S |
6,000,000 |
President |
An,Gyeong Chul |
| Preferred shares O/S |
|
No.of Employees |
168(2007. 6) |
| The sales has grown up due to the sales of Baskan(digestive), Dakspen(antiphlogistics), Amorin(diabetes medicine), Kamrox(arthritis medicine). The sales and the profitability has been down due to the scandal of test on the live animals of the competing company. It will maintain a stable financial structure based on the low borrowing rate and low dependency on the exterior captial. |
| The profitability will go up with the sales of Viscan based on the cost competitiveness as it holding the Visrute bacterial of own grown. Bio new drug such as DC-Vac/EP-L, a cell treatment will be launched in the second half and the large intestine cancer medicine is under clinical test. It has entered into the cell bank and it will use it for the marketing tool to promote sales of cell treatment medicine. It expects a synergetic result fom this move. |
|
  |
(date: 2007.06, unit : %) |
| Name |
Ha Jeongtae |
Jang Oksun |
Lee Baekcheon |
| Portion |
21.6 |
4.0 |
1.6 |
|
 |
(unit : %) |
| Sales |
Tablets |
61.0 |
Cost |
Raw Materials |
|
| Capsule |
21.0 |
Labors |
|
| Eye Drop |
9.9 |
Overhead |
|
|
 |
(Unit : 100Mn.Won,Won) |
| Year |
01. 8 |
05.11 |
- |
- |
- |
| Type |
LI |
RI |
- |
- |
- |
| Amount |
47.00 |
13.00 |
- |
- |
- |
|
|
|
|
